Shefa Arya Nezhad

Dr. Shefa Arya Nezhad

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
RRRaiza Rossi
Raiza Rossi
ANArmin Nouri
Armin Nouri
ZAZafer Akman
Zafer Akman
SNShefa Arya Nezhad
Shefa Arya Nezhad
ADAbdulla A. Damluji
Abdulla A. Damluji
MNMichael G Nanna
Michael G Nanna

2 July 2026 in American Heart Journal
Verified
Journal Article
Closed access
SMSridhar Mangalesh
Sridhar Mangalesh
ZAZafer Akman
Zafer Akman
ANArmin Nouri
Armin Nouri
GBGolsa Babapour
Golsa Babapour
SNShefa Arya Nezhad
Shefa Arya Nezhad
MNMichael G Nanna
Michael G Nanna

24 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
SNShefa Arya Nezhad
Shefa Arya Nezhad
ANArmin Nouri
Armin Nouri
LMLaura Moreines
Laura Moreines
SMSridhar Mangalesh
Sridhar Mangalesh
PRParvaneh Rastgou
Parvaneh Rastgou
MNMichael G Nanna
Michael G Nanna
Despite substantial reductions in atherosclerotic cardiovascular disease (ASCVD) events with intensive low-density lipoprotein cholesterol (LDL-C) lowering, considerable residual cardiovascular risk persists among individuals achieving guideline-recommended LDL-C targets. This residual risk reflects biological pathways not addressed by LDL-C lowering and remains a central challenge in preventive cardiology. This narrative review examines three overlapping domains: residual lipid risk related to triglyceride-rich lipoprotein remnants and excess apolipoprotein B-containing particles; genetically determined lipoprotein(a) [Lp(a)]-mediated risk; and residual inflammatory risk involving the NLRP3 inflammasome and downstream interleukin-1β and interleukin-6 signaling. Complementary biomarkers, including apolipoprotein B, non-HDL cholesterol, remnant cholesterol, Lp(a), and high-sensitivity C-reactive protein, may help characterize residual-risk phenotypes beyond LDL-C alone, although their incremental value and influence on management vary with the strength of prognostic and causal evidence and the availability of effective therapies. Icosapent ethyl and low-dose colchicine have demonstrated cardiovascular benefit in selected high-risk populations, whereas the cardiovascular benefits of therapies targeting apoC-III, ANGPTL3, and Lp(a) remain under evaluation. Recent phase 3 findings have further underscored uncertainty regarding the cardiovascular benefit of interleukin-6 inhibition. Integrating complementary biomarkers with therapies supported by randomized outcomes evidence may enable a more individualized approach to residual cardiovascular risk reduction.

11 August 2026 in The Lancet Healthy Longevity
Verified
Journal Article
Open access
SNShefa Arya Nezhad
Shefa Arya Nezhad
PRParvaneh Rastgou
Parvaneh Rastgou
MNMichael G Nanna
Michael G Nanna

18 June 2026 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
YJYasser Jamil
Yasser Jamil
NJNadim Jaafar
Nadim Jaafar
ANArmin Nouri
Armin Nouri
FAFrancisco B. Alexandrino
Francisco B. Alexandrino
KFKassem Farhat
Kassem Farhat
MNMichael G Nanna
Michael G Nanna